Oncopeptides ABFRA:OND -1.39%30 PB Ratio is 7.48 as of Jun. 27, 2026, which is 68% above its 10-year median of 4.46. GuruFocus rates FRA:OND with a GF Score™ of 30/100 and a GF Value™ of €0.37 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,232 Biotechnology companies, Oncopeptides AB ranks worse than 82.71% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-27), Oncopeptides AB's share price is €0.1422. Oncopeptides AB's Book Value per Share for the quarter that ended in Mar. 2026 was €0.02. Hence, Oncopeptides AB's PB Ratio of today is 7.48.
The historical rank and industry rank for Oncopeptides AB's PB Ratio or its related term are showing as below:
FRA:OND'
s PB Ratio Range Over the Past 10 Years
Min: 0.48 Med: 4.46 Max: 237.07
Current: 7.85
During the past 12 years, Oncopeptides AB's highest PB Ratio was 237.07. The lowest was 0.48. And the median was 4.46.
FRA:OND's PB Ratio is ranked worse than 82.71% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs FRA:OND: 7.85
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Oncopeptides AB was 277.20% per year. The lowest was -58.00% per year. And the median was -22.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Oncopeptides AB PB Ratio Related Terms
Oncopeptides AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Oncopeptides AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oncopeptides AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncopeptides AB PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncopeptides AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Oncopeptides AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Oncopeptides AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Oncopeptides AB (FRA:OND) has a PB Ratio of 7.48 as of Jun. 27, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oncopeptides AB and its competitors. This is 68% above median its historical median of 4.46. Over the past decade, Oncopeptides AB's PB Ratio has ranged from 0.48 to 237.07. According to the industry distribution chart, Oncopeptides AB ranks #1019 out of 1232 companies in the Biotechnology industry, placing it in the top 82.7%.
Is Oncopeptides AB's PB Ratio too high?
Oncopeptides AB's current PB Ratio of 7.48 is 68% above median its 10-year median of 4.46. Over the past 10 years, this metric has ranged from a low of 0.48 to a high of 237.07. The Biotechnology industry median PB Ratio is 2.80. Oncopeptides AB's value of 7.48 is 167.1% above this industry median. Based on the distribution chart, Oncopeptides AB ranks #1019 out of 1232 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Oncopeptides AB has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Oncopeptides AB's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncopeptides AB ranks #1019 out of 1232 companies for PB Ratio. This places Oncopeptides AB in the lower half of its industry. The industry median PB Ratio is 2.80. Oncopeptides AB's value of 7.48 is 167.1% above this benchmark. Historically, Oncopeptides AB's own PB Ratio has ranged from 0.48 to 237.07 over the past decade. While the company's 10-year median is 4.46 vs. the industry median of 2.80, Oncopeptides AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncopeptides AB's current PB Ratio of 7.48 is 167.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oncopeptides AB and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncopeptides AB's current PB Ratio is 7.48, which is 68% above median its own 10-year median of 4.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncopeptides AB stock overvalued right now?
Based on GuruFocus' analysis, Oncopeptides AB (FRA:OND) is currently considered Possible Value Trap. The stock's GF Value™ is €0.37, compared to a current price of €0.14 — trading 61.6% below its estimated fair value. The current PB Ratio is 7.48, which is 68% above median its 10-year median of 4.46 and 167.1% above the Biotechnology industry median of 2.80. Oncopeptides AB's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Oncopeptides AB (FRA:OND), the current PB Ratio is 7.48 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncopeptides AB (FRA:OND) Overvalued in 2026?
Based on GuruFocus' analysis, Oncopeptides AB stock appears to be undervalued.
The current stock price of €0.14 is trading 61.6% below its estimated GF Value™ of €0.37.
GuruFocus considers Oncopeptides AB to be Possible Value Trap.
Key valuation signals for FRA:OND:
PB Ratio: 7.48 (68% above median its 10-year median of 4.46)
GF Value™: €0.37 vs. price of €0.14 (61.6% below fair value)
Industry Position: 167.1% above the Biotechnology median (#1019 of 1232)
No single metric tells the full story. See the FRA:OND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
30GF Score
Get the complete analysis for FRA:OND
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OND has been successfully added to your 
